Genetic immunization:: A new monoclonal antibody for the detection of BCL-6 protein in paraffin sections

被引:12
作者
García, JF
García, JF
Maestre, L
Lucas, E
Sánchez-Verde, L
Romero-Chala, S
Piris, MA
Roncador, G
机构
[1] CNIO, Biotechnol Program, Mol Pathol Program, Monoclonal Antibodies Unit, E-28029 Madrid, Spain
[2] Ctr Nacl Invest Oncol, Histol & Immunochem Unit, E-28029 Madrid, Spain
[3] Ctr Nacl Invest Oncol, Prot Technol Unit, E-28029 Madrid, Spain
关键词
BCL-6; formalin fixed; genetic immunization; monoclonal antibody; lymphomas;
D O I
10.1369/jhc.5A6646.2005
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Genetic immunization can be combined with hybridoma technology to generate high-affinity monoclonal antibodies (MAbs). A new anti-BCL-6 MAb (GI191E/A8) was produced by cloning full-length BCL-6 cDNA into a eukaryotic vector and delivering this into mouse epidermis using a helium gene gun. A comparative study was made of the specificity and the effects of formalin fixation on immunohistochemistry quality of GI191E/A8 and two other anti-BCL-6 MAbs. To evaluate its possible application to differential diagnosis of lymphomas, two tissue microarrays (89 diffuse large B-cell lymphomas and 24 B-cell chronic lymphocytic leukemia cases) were stained with GI191E/A8 and another anti-BCL-6 MAb produced by conventional means. Using GI191E/A8, the detection of BCL-6 protein was significantly increased, and its specificity was independent of formalin-fixation time. Using automatic quantified analysis, the correlation between the two anti-BCL-6 MAbs tested was identical in cases with overexpression or absence of BCL-6. In cases with intermediate BCL-6 protein expression, detection with GI191E/A8 was more sensitive. A significant association of higher BCL-6 expression and longer median overall survival times in diffuse large B-cell lymphomas was found. Using conventionally produced MAbs in the same patient group, the association was not significant.
引用
收藏
页码:31 / 38
页数:8
相关论文
共 23 条
[1]  
BARRY MA, 1994, BIOTECHNIQUES, V16, P616
[2]   High-level generation of polyclonal antibodies by genetic immunization [J].
Chambers, RS ;
Johnston, SA .
NATURE BIOTECHNOLOGY, 2003, 21 (09) :1088-1092
[3]  
Costagliola S, 1998, J IMMUNOL, V160, P1458
[4]  
ERBER WN, 1984, LANCET, V1, P1042
[5]   Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry [J].
Falini, B ;
Mason, DY .
BLOOD, 2002, 99 (02) :409-426
[6]   Hodgkin and Reed-Stemberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints:: analyses using tissue microarrays [J].
García, JF ;
Camacho, FI ;
Morente, M ;
Fraga, M ;
Montalbán, C ;
Alvaro, T ;
Bellas, C ;
Castaño, A ;
Díez, A ;
Flores, T ;
Martín, C ;
Martínez, MA ;
Mazorra, F ;
Menárguez, J ;
Mestre, MJ ;
Mollejo, M ;
Sáez, AI ;
Sánchez, L ;
Piris, MA .
BLOOD, 2003, 101 (02) :681-689
[7]   DIFFERENT EPSTEIN-BARR VIRUS-B CELL-INTERACTIONS IN PHENOTYPICALLY DISTINCT CLONES OF A BURKITTS-LYMPHOMA CELL-LINE [J].
GREGORY, CD ;
ROWE, M ;
RICKINSON, AB .
JOURNAL OF GENERAL VIROLOGY, 1990, 71 :1481-1495
[8]   DNA vaccines: Immunology, application, and optimization [J].
Gurunathan, S ;
Klinman, DM ;
Seder, RA .
ANNUAL REVIEW OF IMMUNOLOGY, 2000, 18 :927-974
[9]  
Harris N L, 2000, Hematol J, V1, P53, DOI 10.1038/sj.thj.6200013
[10]   Tissue microarray technology for high-throughput molecular profiling of cancer [J].
Kallioniemi, OP ;
Wagner, U ;
Kononen, J ;
Sauter, G .
HUMAN MOLECULAR GENETICS, 2001, 10 (07) :657-662